Why did RGS.AX stock spike today?

RGS.AX stock rose on heavy volume of **4,275,678** shares and a **33.33%** price gain, likely driven by speculative trading and pipeline interest. No single public ASX announcement explained the full move; check the Regeneus investor news feed for updates.

What is Meyka AI’s rating for RGS.AX stock?

Meyka AI rates RGS.AX with a score out of 100: **64.99 | Grade: B | Suggestion: HOLD**. The grade weighs benchmarks, sector performance, metrics and forecasts and is informational only.

What price target does Meyka AI have for RGS.AX stock?

Meyka AI's forecast model projects **A$0.020** in 12 months for RGS.AX stock, implying an upside of **66.67%** from the current **A$0.012**. Forecasts are model-based projections and not guarantees.

Is RGS.AX stock suitable for long-term investors?

RGS.AX stock is a speculative small-cap biotech with negative earnings, tight liquidity and development risk. Long-term suitability depends on tolerance for dilution and clinical milestones; many investors prefer to wait for clearer funding or trial outcomes.

AU Stocks

RGS.AX Regeneus Ltd (ASX) +33.33% volume surge 13 Mar 2026: signals trader interest

ByHuzaifa Zahoor March 13, 2026

The RGS.AX stock moved sharply on market close 13 Mar 2026, rising to A$0.012 on a 33.33% intraday gain with 4,275,678 shares traded. This high-volume move on the ASX flagged renewed trader interest in Regeneus Ltd (ASX) after a long low-price base. The spike outpaced the 50-day average price of A$0.00614 and the average daily volume of 616,955, so volume confirms momentum rather than a thin-market blip. We examine catalysts, financials, technical context, and Meyka AI’s grade and forecast to explain what the move means for short-term traders and longer-term investors.